SG11201811292RA - Compositions and methods for the depletion of cells - Google Patents
Compositions and methods for the depletion of cellsInfo
- Publication number
- SG11201811292RA SG11201811292RA SG11201811292RA SG11201811292RA SG11201811292RA SG 11201811292R A SG11201811292R A SG 11201811292RA SG 11201811292R A SG11201811292R A SG 11201811292RA SG 11201811292R A SG11201811292R A SG 11201811292RA SG 11201811292R A SG11201811292R A SG 11201811292RA
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- international
- compositions
- isotype
- december
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 abstract 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 abstract 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 abstract 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 abstract 3
- 230000000779 depleting effect Effects 0.000 abstract 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000001363 autoimmune Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003833 cell viability Effects 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004020 luminiscence type Methods 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662351778P | 2016-06-17 | 2016-06-17 | |
US201662351725P | 2016-06-17 | 2016-06-17 | |
US201662437756P | 2016-12-22 | 2016-12-22 | |
US201662437729P | 2016-12-22 | 2016-12-22 | |
US201762448768P | 2017-01-20 | 2017-01-20 | |
US201762448782P | 2017-01-20 | 2017-01-20 | |
PCT/US2017/038151 WO2017219025A1 (en) | 2016-06-17 | 2017-06-19 | Compositions and methods for the depletion of cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811292RA true SG11201811292RA (en) | 2019-01-30 |
Family
ID=60664586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811292RA SG11201811292RA (en) | 2016-06-17 | 2017-06-19 | Compositions and methods for the depletion of cells |
Country Status (13)
Country | Link |
---|---|
US (4) | US20190328901A1 (de) |
EP (1) | EP3471772A4 (de) |
JP (3) | JP2019522050A (de) |
KR (2) | KR20230082055A (de) |
CN (1) | CN109641051A (de) |
AU (3) | AU2017204139B2 (de) |
BR (1) | BR112018076263A2 (de) |
CA (1) | CA3028145A1 (de) |
IL (1) | IL263743A (de) |
MA (1) | MA45407A (de) |
MX (1) | MX2018015683A (de) |
SG (1) | SG11201811292RA (de) |
WO (1) | WO2017219025A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3019581A1 (en) | 2016-04-04 | 2017-10-12 | Hemogenyx Llc | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies |
MX2020000676A (es) | 2017-07-18 | 2021-05-14 | Csl Behring Gene Therapy Inc | Composiciones y metodos para tratar beta-hemoglobinopatias. |
SG11202010469QA (en) * | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
CN112739340A (zh) * | 2018-07-23 | 2021-04-30 | 美真达治疗公司 | 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
JP2021530545A (ja) * | 2018-07-23 | 2021-11-11 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 同種異系の細胞療法における抗−cd2抗体薬物コンジュゲート(adc)の使用 |
MX2021004579A (es) * | 2018-10-30 | 2021-07-06 | Magenta Therapeutics Inc | Métodos para trasplante de células madre hematopoyéticas alogénicas. |
EP3877416A4 (de) * | 2018-10-30 | 2022-07-27 | Magenta Therapeutics, Inc. | Anti-cd45-antikörper und konjugate davon |
JP2022514955A (ja) | 2018-12-23 | 2022-02-16 | シーエスエル・ベーリング・エルエルシー | ウィスコット・アルドリッチ症候群の造血幹細胞遺伝子治療 |
CN113490504A (zh) * | 2019-01-07 | 2021-10-08 | 美真达治疗公司 | 抗-cd45抗体药物缀合物(adc)在细胞疗法中的用途 |
EP3958910A4 (de) * | 2019-04-24 | 2023-08-02 | Magenta Therapeutics, Inc. | Anti-cd45-antikörper-wirkstoff-konjugate und verwendungen davon |
CN113993550A (zh) * | 2019-04-24 | 2022-01-28 | 美真达治疗公司 | 用于基因疗法的调理方法 |
JP2022530100A (ja) * | 2019-04-25 | 2022-06-27 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法 |
KR20220016922A (ko) * | 2019-06-04 | 2022-02-10 | 마젠타 테라퓨틱스 인코포레이티드 | 자가면역 질환을 치료하기 위한 방법 및 조성물 |
KR20220032568A (ko) * | 2019-06-25 | 2022-03-15 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
EP3997128A4 (de) * | 2019-07-09 | 2023-10-18 | Hemogenyx Pharmaceuticals Llc | Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern |
US20220296727A1 (en) * | 2019-07-30 | 2022-09-22 | Dendrocyte Biotech Pty Ltd | Immunoconjugate |
IL292628A (en) * | 2019-11-01 | 2022-07-01 | Magenta Therapeutics Inc | Anti-cd45 antibody and conjugates accordingly |
WO2021168128A1 (en) * | 2020-02-18 | 2021-08-26 | Magenta Therapeutics, Inc. | Compositions and methods for allogeneic transplantation |
AU2022422572A1 (en) | 2021-12-23 | 2024-06-06 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd45 for use in cell therapy |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6074650A (en) | 1985-06-24 | 2000-06-13 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
WO1990009799A1 (en) | 1989-02-23 | 1990-09-07 | Colorado State University Research Foundation | GnRH ANALOGS FOR DESTROYING GONADOTROPHS |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6106834A (en) | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
US6024957A (en) | 1993-06-02 | 2000-02-15 | Research Corporation Technologies, Inc. | Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same |
GB9323199D0 (en) | 1993-11-10 | 1994-01-05 | Falkenberg J H F | Leukaemia treatment |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2003048327A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection |
NZ545605A (en) * | 2003-09-18 | 2009-03-31 | Novartis Ag | Humanised antibodies binding to CD45RO and CD45RB |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP1661584A1 (de) | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Anwendung von Amatoxin-Konjugaten und Phallotoxin-Konjugaten mit Makromolekülen zur Krebstherapie und Therapie von Entzündungen |
US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
WO2007087453A2 (en) | 2006-01-27 | 2007-08-02 | Cellerant Therapeutics, Inc. | Compositions and methods for treating haematological proliferative disorders |
EP1993608A1 (de) | 2006-03-10 | 2008-11-26 | Diatos | Über einen enzym-spaltbaren linker an einen antikörper konjugierte arzneimittel gegen krebs |
EP1859811B1 (de) | 2006-05-27 | 2011-08-24 | Faulstich, Heinz, Dr. | Anwendung von Amatoxin-Konjugaten und Phallotoxin-Konjugaten mit Makromolekülen zur Krebstherapie und Therapie von Entzündungen |
TWI523864B (zh) | 2006-05-30 | 2016-03-01 | 建南德克公司 | 抗體及免疫接合物及其用途 |
WO2008045976A2 (en) * | 2006-10-10 | 2008-04-17 | Squicor | Compositions and methods for treating and diagnosing cancers |
EP3255061B1 (de) * | 2006-11-03 | 2021-06-16 | The Board of Trustees of the Leland Stanford Junior University | Selektive immundepletion einer endogenen stammzellennische zur transplantation |
ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
US8362213B2 (en) * | 2009-04-01 | 2013-01-29 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
CA2970774C (en) | 2009-04-08 | 2019-01-08 | Deutsches Krebsforschungszentrum | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
MX2011010469A (es) | 2009-04-08 | 2012-03-14 | Deutsches Krebsforsch | Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer. |
EA024118B1 (ru) | 2010-04-15 | 2016-08-31 | Сиэтл Дженетикс, Инк. | Конъюгаты пирролбензодиазепина направленного действия |
EP2436398B1 (de) | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxinkonjugate mit verbesserten Linkern |
EP2497499A1 (de) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxinkonjugate mit verbesserten Verknüpfungen |
US9987308B2 (en) * | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
ES2744226T3 (es) | 2011-05-08 | 2020-02-24 | Legochem Biosciences Inc | Conjugados de proteína-agente activo y método para preparar los mismos |
AU2012322932B2 (en) | 2011-10-14 | 2016-11-10 | Medimmune Limited | Pyrrolobenzodiazepines |
KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
EP2684865A1 (de) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Verfahren zum Synthetisieren eines Amatoxinbausteins und von Amatoxinen |
US20150218220A1 (en) | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
US9324898B2 (en) * | 2012-09-25 | 2016-04-26 | Alliance For Sustainable Energy, Llc | Varying cadmium telluride growth temperature during deposition to increase solar cell reliability |
EA201591049A1 (ru) | 2012-11-30 | 2015-09-30 | Новартис Аг | Способы получения конъюгатов дисульфидсодержащих белков |
EP2961828A4 (de) | 2013-02-28 | 2016-08-03 | Harvard College | Zusammensetzungen und verfahren zur mobilisierung von stammzellen |
EP2774624A1 (de) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxinderivate |
EP2968591A1 (de) * | 2013-03-15 | 2016-01-20 | Novartis AG | Zellproliferationshemmer und konjugate davon |
EP2777714A1 (de) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Verfahren zur Herstellung eines Immunoliganden/Nutzlastkonjugats durch ein Sequenz-spezifisches Transpeptidase Enzym |
US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
CN105377307B (zh) | 2013-06-24 | 2019-09-24 | Abl生物公司 | 具有改进的稳定性的抗体-药物缀合物及其用途 |
FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
JP6321687B2 (ja) * | 2014-03-10 | 2018-05-09 | ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマトキシン誘導体 |
US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
US20170226209A1 (en) * | 2014-08-01 | 2017-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An anti-cd45rc antibody for use as drug |
BR112017006602A2 (pt) | 2014-10-01 | 2017-12-19 | Medimmune Llc | método de conjugação de um polipeptídeo |
WO2016064749A2 (en) | 2014-10-20 | 2016-04-28 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
EP3215519A1 (de) * | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxinderivate und konjugate davon als inhibitoren der rna-polymerase |
EP3026060A1 (de) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | CD45R0-spezifischer, humanisierter Antikörper oder Fragment davon |
US9729129B2 (en) * | 2014-12-05 | 2017-08-08 | Bhaskar Gopalan | System and method for reducing metastability in CMOS flip-flops |
US20160220687A1 (en) | 2015-02-02 | 2016-08-04 | National Guard Health Affairs | Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer |
HRP20240075T1 (hr) | 2015-03-09 | 2024-03-29 | Heidelberg Pharma Research Gmbh | Konjugati amatoksin-protutijela |
BR112017021536A2 (pt) * | 2015-04-06 | 2018-07-03 | Harvard College | composições e métodos para o condicionamento não mieloablativo |
ES2844623T3 (es) | 2015-05-21 | 2021-07-22 | Actinium Pharmaceueuticals Inc | Administración de infusión de anticuerpos monoclonales conjugados |
WO2017051249A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
CN108495840A (zh) | 2015-11-27 | 2018-09-04 | 海德堡医药研究有限责任公司 | γ-鹅膏菌素的衍生物 |
EP3222292A1 (de) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitinkonjugate |
EP3426305A4 (de) | 2016-03-07 | 2020-01-08 | Actinium Pharmaceuticals, Inc. | Stabilisierte radioaktiv markierte anti-cd45-immunglobulinzusammensetzungen |
MY197235A (en) | 2016-04-20 | 2023-06-07 | Hangzhou Dac Biotech Co Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
WO2017205587A1 (en) | 2016-05-27 | 2017-11-30 | Actinium Pharmaceuticals, Inc. | Low dose antibody-based methods for treating hematologic malignancies |
JP7103953B2 (ja) | 2016-05-31 | 2022-07-20 | ソレント・セラピューティクス・インコーポレイテッド | 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート |
KR20230066647A (ko) | 2016-06-17 | 2023-05-16 | 마젠타 테라퓨틱스 인코포레이티드 | Cd117+ 세포의 고갈을 위한 조성물 및 방법 |
CN110023489A (zh) | 2016-08-29 | 2019-07-16 | Pdi医药发展国际股份公司 | 提供治疗活性细胞产物 |
US10112266B2 (en) * | 2016-09-09 | 2018-10-30 | Baltic Innovation Holding PRO, AS | Pressed thermite rod for a self-contained portable cutting device |
JP7360323B2 (ja) * | 2016-10-13 | 2023-10-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨髄非破壊前処理のための組成物および方法 |
BR112019012937A2 (pt) | 2016-12-23 | 2019-12-10 | Heidelberg Pharma Res Gmbh | novo conjugado de amanitina |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
BR112019015342A2 (pt) | 2017-01-30 | 2020-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Regime de condicionamento não genotóxico para o transplante de células-tronco |
JP7220199B2 (ja) | 2017-08-07 | 2023-02-09 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマニチンの新規な合成方法 |
-
2017
- 2017-06-19 US US16/310,738 patent/US20190328901A1/en not_active Abandoned
- 2017-06-19 JP JP2019518185A patent/JP2019522050A/ja active Pending
- 2017-06-19 EP EP17814261.8A patent/EP3471772A4/de active Pending
- 2017-06-19 AU AU2017204139A patent/AU2017204139B2/en active Active
- 2017-06-19 CN CN201780050855.7A patent/CN109641051A/zh active Pending
- 2017-06-19 SG SG11201811292RA patent/SG11201811292RA/en unknown
- 2017-06-19 KR KR1020237017708A patent/KR20230082055A/ko not_active Application Discontinuation
- 2017-06-19 BR BR112018076263-6A patent/BR112018076263A2/pt not_active IP Right Cessation
- 2017-06-19 CA CA3028145A patent/CA3028145A1/en active Pending
- 2017-06-19 KR KR1020197001536A patent/KR20190039085A/ko not_active Application Discontinuation
- 2017-06-19 MX MX2018015683A patent/MX2018015683A/es unknown
- 2017-06-19 MA MA045407A patent/MA45407A/fr unknown
- 2017-06-19 WO PCT/US2017/038151 patent/WO2017219025A1/en active Application Filing
-
2018
- 2018-07-27 AU AU2018208749A patent/AU2018208749B2/en active Active
- 2018-12-16 IL IL263743A patent/IL263743A/en unknown
-
2019
- 2019-02-28 US US16/289,388 patent/US10624973B2/en active Active
-
2020
- 2020-04-20 US US16/853,619 patent/US20200376134A1/en not_active Abandoned
- 2020-08-11 AU AU2020217338A patent/AU2020217338A1/en not_active Abandoned
-
2022
- 2022-07-21 JP JP2022116511A patent/JP2022163075A/ja active Pending
-
2023
- 2023-11-03 US US18/501,451 patent/US20240207428A1/en not_active Abandoned
- 2023-12-11 JP JP2023208327A patent/JP2024037832A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017219025A1 (en) | 2017-12-21 |
KR20190039085A (ko) | 2019-04-10 |
US10624973B2 (en) | 2020-04-21 |
US20190192682A1 (en) | 2019-06-27 |
EP3471772A4 (de) | 2020-03-18 |
JP2024037832A (ja) | 2024-03-19 |
JP2019522050A (ja) | 2019-08-08 |
US20240207428A1 (en) | 2024-06-27 |
AU2020217338A1 (en) | 2020-08-27 |
AU2017204139B2 (en) | 2018-08-09 |
MA45407A (fr) | 2019-04-24 |
AU2018208749A1 (en) | 2018-08-16 |
AU2018208749B2 (en) | 2020-09-03 |
MX2018015683A (es) | 2019-05-27 |
JP2022163075A (ja) | 2022-10-25 |
EP3471772A1 (de) | 2019-04-24 |
CN109641051A (zh) | 2019-04-16 |
AU2017204139A1 (en) | 2018-01-18 |
US20190328901A1 (en) | 2019-10-31 |
BR112018076263A2 (pt) | 2019-03-26 |
US20200376134A1 (en) | 2020-12-03 |
IL263743A (en) | 2019-01-31 |
CA3028145A1 (en) | 2017-12-21 |
KR20230082055A (ko) | 2023-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201810883TA (en) | Combination therapy | |
SG11201810640RA (en) | Cd33 specific chimeric antigen receptors | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201808920RA (en) | Genome editing of human neural stem cells using nucleases | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201808913WA (en) | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells |